Post-earnings recap
Reported
Thu, Aug 8, 2024
EPS actual
$-1.38
EPS est.
$-0.58
EPS surprise
-138.75%
1-day move
+3.40%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Arrowhead Pharmaceuticals reported a larger-than-expected loss per share, which typically raises concerns among investors. However, the stock rose by 3.40%, likely driven by optimism about ongoing clinical trials and product development efforts. The lack of revenue data and guidance may leave investors uncertain about the company's near-term outlook.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.38 | N/A | -138.75% |
| Revenue | N/A | N/A | N/A |
Management expressed caution regarding current financial performance. They emphasized their commitment to advancing their pipeline despite the lack of guidance.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The focus remains on ongoing clinical trials and product development.